Eisai H3B-6527-G000-101: for Advanced Hepatocellular Carcinoma
What is the Purpose of this Study?
Who Can Participate in this Study?
- Have advanced hepatocellular carcinoma or intrahepatic cholangiocarcinoma
- Have had treatment with sorafenib if you have HCC or have had cisplatin/oxaliplatin if you have ICC
What is Involved?
If you choose to join this study, you will:
- Take the study drug, called H3B-6527, by mouth every day in 21 day cycles
- Continue to take the study drug as long as the study doctors thinks it is safe